No Data
No Data
Earnings Preview: Zymeworks to Report Financial Results Post-market on October 31
Zymeworks Reports New Preclinical Data From ADC Candidates ZW220 and ZW251
Zymeworks Begins Trial for Promising Cancer Therapy
ZymeWorks Has Dosed The First Patient In The First-In-Human Phase 1 Trial To Evaluate The Safety And Tolerability Of The Investigational Therapy ZW171 For Advanced Or Metastatic Ovarian Cancer, NSCLC, And Other MSLN-expressing Cancers
Express News | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks Announces Board Changes With New Appointments